过氧化物酶体增殖物激活受体γ基因多态性（rs1801282）与埃及冠心病合并2型糖尿病患者的肥胖相关。
Peroxisome proliferator-activated receptor-γ polymorphism (rs1801282) is associated with obesity in Egyptian patients with coronary artery disease and type 2 diabetes mellitus.
作者信息
Hasan Nehal Salah, Kamel Solaf Ahmed, Hamed Mona, Awadallah Eman, Rahman Amany Hosny Abdel, Musa Nevine Ibrahim, Hussein Ghada Hussein Sayed
机构信息
Department of Clinical and Chemical Pathology, National Research Centre (NRC), Cairo, Egypt.
Department of Internal Medicine, Ain Shams University, Cairo, Egypt.
出版信息
J Genet Eng Biotechnol. 2017 Dec;15(2):409-414. doi: 10.1016/j.jgeb.2017.08.002. Epub 2017 Aug 8.
OBJECTIVE
Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) gene is one of the possible genes linking diabetes mellitus (DM) with coronary artery disease (CAD). The aim of this study is to clarify whether PPAR-γ Pro12Ala polymorphism is associated with the development of CAD in type 2 diabetic patients and to evaluate PPAR-γ Pro12Ala polymorphism genetic distribution in type 2 DM (T2DM) Egyptian subjects.
METHODS
PPAR-γ Pro12Ala polymorphism was determined by Real-Time PCR in serum of 405 subjects classified into 4 groups; T2DM patients (n = 105), T2DM with CAD (n = 100), CAD patients (n = 100) and healthy controls (n = 100).
RESULTS
The PPAR-γ Pro12Ala polymorphism was associated significantly with T2DM with CAD (group2) (OR = 3, 95% CI = (1.5-6); p = 0.001). In this study, T2DM with CAD complications carrying the PPAR-γ Pro12Ala polymorphism had higher BMI than those without the PPAR-γ Pro12Ala polymorphism (p < 0.0001). CAD patients carrying PPAR-γ Pro12Ala polymorphism had considerable insulin resistance features. Plasma paraoxanase 1(PON1) level was considerably reduced among our 3 studied groups in comparison to control group (p < 0.001).
CONCLUSIONS
PPAR-γ Pro12Ala polymorphism might represent a novel risk factor for CAD in T2DM.
目的
过氧化物酶体增殖物激活受体-γ（PPAR-γ）基因是将糖尿病（DM）与冠状动脉疾病（CAD）联系起来的可能基因之一。本研究的目的是阐明PPAR-γ Pro12Ala多态性是否与2型糖尿病患者CAD的发生相关，并评估PPAR-γ Pro12Ala多态性在2型糖尿病（T2DM）埃及受试者中的基因分布。
方法
通过实时聚合酶链反应（Real-Time PCR）测定405名受试者血清中的PPAR-γ Pro12Ala多态性，这些受试者分为4组：2型糖尿病患者（n = 105）、合并CAD的2型糖尿病患者（n = 100）、CAD患者（n = 100）和健康对照者（n = 100）。
结果
PPAR-γ Pro12Ala多态性与合并CAD的2型糖尿病（第2组）显著相关（比值比[OR] = 3，95%置信区间[CI] =（1.5 - 6）；p = 0.001）。在本研究中，携带PPAR-γ Pro12Ala多态性的合并CAD并发症的2型糖尿病患者的体重指数（BMI）高于未携带PPAR-γ Pro12Ala多态性的患者（p < 0.0001）。携带PPAR-γ Pro12Ala多态性的CAD患者具有相当明显的胰岛素抵抗特征。与对照组相比，我们研究的3组患者血浆对氧磷酶1（PON1）水平均显著降低（p < 0.001）。
结论
PPAR-γ Pro12Ala多态性可能是2型糖尿病患者CAD的一个新的危险因素。
Zotero 插件